Hemostemix Inc (SWB:2VF0) Financings
Financings
| Raise | Date | In US dollars |
|---|---|---|
| Private placement of units Tranche closed: C$380,500 in the latest tranche · C$0.05 a unit · ½ warrant at C$0.12 for 24 months Use of proceeds: ACP-01 manufacturing, clinical-program preparation, regulatory submissions, physician education and general working capital | Oct 7, 2026 | |
| Private placement of units Tranche closed: C$360,000 raised · C$0.05 a unit · ½ warrant at C$0.12 for 24 months Insiders: Certain directors of the Company participated, directly and indirectly, in the Offering Use of proceeds: Sales, marketing, patient acquisition and commercialization; ACP-01 production; Bahamas regulatory fees; working capital | Jun 26, 2026 | |
| Private placement of units Announced: up to C$1M · C$0.05 a unit · ½ warrant at C$0.12 for 24 months Insiders: Certain directors of the Company may participate in the private placement, a related party transaction under MI 61-101 Use of proceeds: Sales, marketing, patient acquisition, physician education, commercialization, ACP-01 production, Bahamas regulatory fees and working capital | Jun 17, 2026 | US$712,555 |
| Private placement of common shares Closed: C$480,000 raised · C$0.12 a share Use of proceeds: General working capital, including regulatory, clinical and commercialization work on ACP-01 (VesCell) | Dec 31, 2025 | US$350,212 |
| Private placement of units Closed: C$518,440 raised · C$0.11 a unit · 1 warrant at C$0.15 for 24 months Buyers: Director of the Company (participating in the Offering) Insiders: Certain directors participated directly and indirectly Use of proceeds: General working capital and ongoing operations, including marketing and sales of VesCell | Dec 2, 2025 | |
| Private placement of common shares Closed: C$280,594 raised · C$0.125 a share Insiders: The investor is arm's length and not a Related Party to the Company. Use of proceeds: General working capital, ongoing operating expenses and business development. | Nov 18, 2025 | US$200,467 |
| Therapy Convertible Debenture Tranche closed: US$1.14M raised Use of proceeds: General working capital, corporate overhead and research and development activities | Aug 20, 2025 | |
| Private placement of units Closed: C$2.97M raised · C$0.1 a unit · 1 warrant at C$0.15 for 24 months Buyers: Peter Lacey (subscribed for $1,500,000); Loran Swanberg (subscribed for $100,000); Mr. Lacey (subscribed to 15,000,000 Units; now owns 24,316,937 Common Shares (13.40% non-diluted)) Insiders: Directors Peter Lacey and Loran Swanberg directly and indirectly participated; related party transaction under MI 61-101 Use of proceeds: Repay CD#1 in full at a 50% discount ($1,250,000) and general working capital, including marketing and sales of VesCell | Jul 31, 2025 | US$2.18M |
| Private placement of common shares Closed: C$469,366 raised · C$0.12 a share Insiders: The investor is arm's length to the Company and is not a Related Party Use of proceeds: General working capital, operational expenses and business development | Jul 4, 2025 | US$345,046 |
| Private placement of common shares Closed: US$336,500 raised · C$0.295 a share Buyers: CytoImmune (USD $336,500 for 1,634,466 Common Shares); CytoImmune Therapeutics LLC (1,634,466 Common Shares at CAD $0.295 each) Use of proceeds: General working capital, including business development activities | May 12, 2025 | |
| Private placement of units Closed: C$2.73M raised · C$0.05 a unit · 1 warrant at C$0.12 for 24 months Insiders: Certain directors of the Company participated in the Offering, a related party transaction under MI 61-101 Use of proceeds: Advance stem cell therapeutics platform, initiate sales and process initial ACP batches, pay fees, and general working capital | Dec 3, 2024 |